ClinicalTrials.gg
RecruitingNCT05160870Updated Jan 12, 2022

Genotype-phenotype Correlation and Pathogenic Mechanism in Hereditary Ataxia

An observational study in Hereditary Ataxia, sponsored by Second Affiliated Hospital, School of Medicine, Zhejiang University. Recruiting at 1 site in China. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2022-01-12.

Sponsored by Second Affiliated Hospital, School of Medicine, Zhejiang University · Observational

From the registry’s dates

  • Primary completion was expected by Dec 2022, 3 years 10 months ago, but the record still lists the study as recruiting.
  • Started Jun 2021; still recruiting 5 years 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
500
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-14

Among 10 studies in Spinocerebellar Degenerations with a site in China — 7 open to participants now, 7 under way, 2 of them phase 3. Spinocerebellar Degenerations · China.

Started
2021
with 1 other
Observational
3 of 10
3 open now
Registered
3rd of 10
by date
Lead sponsor
3 of 10
Second Affiliated Hospital, School of Medicine, Zhejiang University

Among the 10 studies in Spinocerebellar Degenerations with a site in China, this one is one of 2 that started in 2021, is one of 3 observational ones, and was the 3rd registered.

Spinocerebellar Degenerations

49 studies on the registry are indexed under Spinocerebellar Degenerations; 15 are open to participants now.

Browse Spinocerebellar Degenerations studies →

Open to participants now

7 of the 10 studies in Spinocerebellar Degenerations with a site in China are open now. Recruiting first, the newest first:

1 more — sign in →

All 7 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 9 Spinocerebellar Degenerations studies recruiting now, 5 set no upper age limit and 3 stop at 75 or younger; 4 take children under 18; 1 takes healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Watch this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies in Spinocerebellar Degenerations with a site in China, or all of them as a file.
02

Study summary

The investigators aimed to find appropriate biomarkers such as serum neurofilament light chain in reflecting disease severity in hereditary ataxia from a large cohort during long-term follow-up. The disease severity is indicated by clinical scales and brain MRI tests.

03

Conditions studied

  • Hereditary Ataxia
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

patients with Spinocerebellar ataxia

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • genetically diagnosed as Spinocerebellar ataxia

Exclusion criteria

Exclusion Criteria:

  • deny follow-yp
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
500 participants (estimated)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. Serum neurofilament light chain

    Serum neurofilament light chain levels were collected among patients in preclinical or mild stage of Spinocerebellar ataxia, especially type 3.

    Time frame: from 2021 to 2025

07

Study locations

1 of 1 sites recruiting
  • Second Affiliated Hospital, Zhejiang University School of Medicine
    Hangzhou, Zhejiang 310005, China
    Recruiting
    • Yi Dong · Contact
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jun 2021 (actual). Primary completion is estimated for Dec 2022, 17 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 6, 2021
First posted
Dec 16, 2021
StartActual
Jun 30, 2021
Primary completionEst.
Dec 25, 2022
CompletionEst.
Dec 25, 2025
Last update
Jan 12, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 12, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05160870
Responsible party
Sponsor
First posted
Dec 16, 2021
Start date
Jun 30, 2021
Primary completion
Dec 25, 2022 (estimated)
Completion
Dec 25, 2025 (estimated)
Last update
Jan 12, 2022

Study contacts

Yi Dong
Contact
dongyi720@zju.edu.cn
+ 8618367129345

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion